제일약품

271980KOSPI

60.0 / 100

Reference Date: 2026-10-23

Financial Score29.5 / 40

News Sentiment12.5 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Declined 10.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Jeil Pharm was established in 2017 through a spin-off from Jeil Pharma Holdings, focusing on the manufacturing and sales of finished pharmaceutical products. Its subsidiary, Oncol Therapeutics, specializes in new drug development. Key products include treatments for hypercholesterolemia, hyperlipidemia, and gastric cancer, with major revenue contributors being Lipito tablets and Lyrica capsules.

Number of Employees

1,011people

Average Salary

63.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

4.09Industry Average 15.008.0Point

Half of industry avg (excellent)

PBR

0.52Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

13.61Industry Average 8.005.5Point

1.7x industry avg (good)

Debt Ratio

6.81Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼53.7% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 0.3% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 8,890Won52-week high 17,39052-week low 8,890

1-month return1.0Point

1m -10.38% (falling)

Volume trend6.0Point

Volume surge

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0